Preclinical studies have established that CD8+ T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4+ T cells and CD40/ CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.
|Original language||English (US)|
|State||Published - 2014|
- Adaptive immunity
ASJC Scopus subject areas
- Immunology and Allergy